Swedish Orphan Biovitrum AB
At the Swedish Orphan Biovitrum AB general meeting 8 May 2025, Folketrygdfondet, manager of the Government Pension Fund Norway, voted against item 16.00, 17.01.01, 17.02.01 and 17.03 for the following reasons:
Item 16.00: Remuneration Report
Folketrygdfondet’s decision to vote against the executive Remuneration Report is based on a cumulative assessment. The report provides insufficient disclosure to assess how — and lacks reasoning to explain why — the executive remuneration strategy aligns with shareholder interests. Therefore, we voted against this item.
Item 17.01.01: Adoption of Share-Based Incentives (Management)
Folketrygdfondet’s decision to vote against the Adoption of Share-Based Incentives is based on a cumulative assessment taking into consideration insufficient disclosure to assess how — and lacks reasoning to explain why — the executive remuneration strategy aligns with shareholder interests. Therefore, we voted against this item.
Item 17.02.01: Issue, Repurchase and Transfer Shares Pursuant to Management Programme
Folketrygdfondet’s decision to vote against the Issue, Repurchase and Transfer Shares Pursuant to Management Programme is based on a cumulative assessment taking into consideration insufficient disclosure to assess how - and lacks reasoning to explain why - the executive remuneration strategy aligns with shareholder interests. For this reason, we voted against this item.
Item 17.03: Approve Equity Swap Agreement
Folketrygdfondet’s decision to vote against the Equity Swap Agreement is based on a cumulative assessment taking into consideration insufficient disclosure to assess how and lack of reasoning to explain the rationale for if and to what extent the executive remuneration strategy aligns with shareholder interests. For this reason, we voted against this item.